Is there a role for PORT in a N1+ NSCLC patient who refuses chemotherapy after lobectomy?
Would an excellent KPS, LVSI+ or poorly differentiated histology change your decision? Would you base your decision on the ANITA trial where subset anaysis showed a benefit for PORT in those patients who refuse chemotherapy (obviously discussing potential cardiac morbidity)?
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · University of Toronto
Answered on
A few caveats to consider - is the patient refusing adjuvant chemo, or are there competing risks (cardiac, age etc) that may attenuate the absolute benefit of adjuvant chemo?
EGFR / ALK status ? PD-1/PD-L1 status? (there are adjuvant trials evaluating other systemic options)
In the absence of other op...
Join for free or sign in to see the full answer